SCANDIDERMA AS • 895238902 • Tromsø • Manufacture of basic pharmaceutical products and pharmaceutical preparations

This website uses cookies to enhance the user experience.

Industry and manufacturing

/ Process industry

SCANDIDERMA AS

Keywords

productionmedicinal substancesdrugsantibioticsbasic vitaminssalicylic acido-acetylsalicylic acidprocessing of blood

Organization

CEO: GH
Geir Håvard Kvalheim1977
Chairman of the board: GH
Geir Håvard Kvalheim1977
Years since formation: 15 years; since Mar 2, 2010
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 241,149; 1 share class
Total number of shareholders: 18; 9 companies, 9 persons

Financials

Total operating income 2023: 1,053,429; NOK
Annual total result 2023: -216,206; NOK
Total equity 2023: -7,205,818; NOK

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
GH Geir Håvard Kvalheim 1977	Managing Director/CEO	17.6 % indirectly

Board

Name	Role	Shares
GH Geir Håvard Kvalheim 1977	Chairman	17.6 % indirectly
EM Edel Margrete Kandal 1958	Board Member	9.59 % indirectly
KH Kai-Hugo Hebnes 1978	Board Member	18.34 % indirectly
CS Carstein Seeberg 1962 Resigned	Board Member	14.15 % indirectly

Top 10 individual shareholders

Name	Role	Shares
KH Kai-Hugo Hebnes 1978	Board Member	18.34 % indirectly
GH Geir Håvard Kvalheim 1977	Managing Director/CEO, Chairman	17.6 % indirectly
CS Carstein Seeberg 1962	Board Member	14.15 % indirectly
AK Anton Kandal 1955	-	9.59 % indirectly
EM Edel Margrete Kandal 1958	Board Member	9.59 % indirectly
IF Ingmar Fimreite 1965	-	5.35 % directly 4.15 % indirectly 1.2 %
TE Thomas Echroll 1977	-	3 % indirectly
JE Jo Erik Johnsrud Klaveness 1953	-	2.07 % indirectly
RT Rudi Thomassen 1980	-	2.07 % indirectly
AR Arild Rune Klakegg 1974	-	2.07 % directly 1.87 % indirectly 0.21 %

Last update: Sep 13, 2023

Ownership

Company shareholders

Name	Share class	Number of shares	Share
G GHK INVEST AS	Ordinary shares	85,000	35.25 %
K KANDAL INVEST AS	Ordinary shares	46,231	19.17 %
S SEEBERG HOLDING AS	Ordinary shares	34,125	14.15 %
I IMPETO AS	Ordinary shares	14,492	6.01 %
IM Inv International Montecristo	Ordinary shares	12,050	5 %
BJ Bartosik Jacek	Ordinary shares	10,000	4.15 %
IF Ingmar Fimreite 1965	Ordinary shares	10,000	4.15 %
D DRUG DISCOVERY LABORATORY AS	Ordinary shares	5,000	2.07 %
R R3 HOLDING AS	Ordinary shares	5,000	2.07 %
L LAVOLD INVEST AS	Ordinary shares	5,000	2.07 %
AR Arild Rune Klakegg 1974	Ordinary shares	4,500	1.87 %
F FIMREITE AS	Ordinary shares	2,898	1.2 %
RS Remi Lunde Solbakken 1987	Ordinary shares	2,173	0.9 %
AK Arthur Knutsen 1983	Ordinary shares	1,449	0.6 %
BN Bård Stian Nybø 1987	Ordinary shares	1,449	0.6 %
DM Daniel Eriksen Martinsen 1978	Ordinary shares	641	0.27 %
CR Christoffer Ryan 1987	Ordinary shares	641	0.27 %
K KLAKEGG HOLDING AS	Ordinary shares	500	0.21 %

Last update: May 24, 2024

Financials

in NOK

Summary

Year	2023	2022	2021
Total operating income	1,053,429	2,702,100	850,857
Annual Total Result	-216,206	-948,397	-580,244
Total assets	409,850	3,378,654	2,743,778
Total liabilities	7,615,668	10,368,266	8,784,993
Total equity	-7,205,818	-6,989,612	-6,041,215

P&L

Year	2023	2022	2021
Total operating income	1,053,429	2,702,100	850,857
Total operating costs	1,269,592	3,646,446	972,735
Operating result	-216,163	-944,346	-121,878
Financial income/costs	-43	-4,050	-458,365
Profit before tax	-216,206	-948,397	-580,244
Total tax & extraordinary income/cost	0	0	0
Annual Total Result	-216,206	-948,397	-580,244

Balance overview

Year	2023	2022	2021
Total fixed assets	383,125	530,033	831,829
Total current assets	26,725	2,848,620	1,911,949
Total assets	409,850	3,378,654	2,743,778
Short term debt	2,567,376	5,250,124	2,948,851
Long term debt	5,048,292	5,118,142	5,836,142
Total liabilities	7,615,668	10,368,266	8,784,993
Contributed capital	6,414,688	6,414,688	6,414,688
Retained earnings	-13,620,507	-13,404,300	-12,455,904
Total equity	-7,205,818	-6,989,612	-6,041,215
Total equity and liabilities	409,850	3,378,654	2,743,778

Classification

Category

Industry and manufacturing

/ Process industry

Type of organization

Limited company

Classification of institutional sector

INNL

Domestic sectors

A_IKKE-FIN

Non-financial corporations

2100

Private non-financial incorporated enterprises

Standard industrial classification

C

Main industrial area

Manufacturing

21

Activity

Manufacture of basic pharmaceutical products and pharmaceutical preparations

21.1

Main industrial group

Manufacture of basic pharmaceutical products

21.10

Industrial group

Manufacture of basic pharmaceutical products

21.100

Industrial group

Manufacture of basic pharmaceutical products